Kintor Pharma successfully dosed the first patient in a Phase II trial for KX-826 for acne vulgaris. Users are more interested in results for male pattern baldness (MPB).
Clascoterone is being discussed as a promising new hair loss treatment, showing significant improvement in trials. Despite this, skepticism persists about its effectiveness, cost, and side effects, with some users preferring minoxidil and finasteride.
The conversation is about finding reputable clinics in Belgium, the Netherlands, France, or Germany for PRP with double centrifugation or exosome therapy for hair loss. The user seeks recommendations based on personal experiences or good reviews.
The conversation humorously discusses hair loss treatments, focusing on finasteride, dutasteride, minoxidil, and microneedling. Users share experiences and opinions on the effectiveness and side effects of these treatments.
The conversation is about the potential cost of GT20029 if FDA approved, with estimates around $150/month. Comparisons are made between GT20029, finasteride, and their mechanisms and side effects.
Trans women discuss using finasteride and dutasteride for hair loss and whether to continue after testosterone suppression. One user reduced dutasteride dosage after achieving undetectable testosterone levels.
The conversation is about a user's one-year hair loss treatment using dutasteride, oral and topical minoxidil, ketoconazole, tretinoin, and PRP. Users discuss treatment effectiveness, potential issues with diffuse thinning, and sourcing affordable treatments.